Publications by authors named "A Zduniak"
We aimed to explore the predictive value of total metabolic tumor volume (TMTV) and beta-2-microglobulin (B2M) levels in patients with follicular lymphoma (FL) with a high tumor burden receiving standard first-line immunochemotherapy. We analyzed 125 patients with the following characteristics: median age, 61 years (55; 67), advanced-stage disease, 88.8%; high FLIPI, 49.
View Article and Find Full Text PDFThe prognostic value of radiomic quantitative features measured on pre-treatment F-FDG PET/CT was investigated in patients with follicular lymphoma (FL). We conducted a retrospective study of 126 FL patients (grade 1-3a) diagnosed between 2006 and 2020. A dozen of PET/CT-derived features were extracted via a software (Oncometer3D) from baseline F-FDG PET/CT images.
View Article and Find Full Text PDFComplete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report.
Clin Case Rep
June 2023
Key Clinical Message: This case report highlights the potential of belinostat for the treatment of relapsed/refractory peripheral T-cell lymphomas, for which effective therapies are still scarce.
Abstract: Peripheral T-cell lymphomas have an aggressive disease course associated with poor outcomes. We report a young patient with highly pretreated relapsed/refractory nodal follicular helper T-cell lymphoma (angioimmunoblastic-type [nTFHL-AI]), who successfully received an allogeneic stem cell transplantation following belinostat therapy.
Background & Aims: We aimed to evaluate body composition (BC) by computed tomography (CT) in hematologic malignancy (HM) patients admitted to the intensive care unit (ICU) for sepsis or septic shock.
Methods: We retrospectively assessed BC and its impact on outcome of 186 patients at the 3rd lumbar (L3) and 12th thoracic vertebral levels (T12) using CT-scan performed before ICU admission.
Results: The median patient age was 58.
Article Synopsis
- A retrospective study was conducted on 433 patients with DLBCL or FL who underwent R-CHOP-like immunochemotherapy between 2006 and 2017 to evaluate cardiovascular toxicity and treatment discontinuation.
- The study identified three types of cardiovascular toxicity: early-onset (within 6 months), subacute (6 months to 1 year), and late (1 year or more after treatment).
- Out of the patients, 11.1% experienced anthracycline-related cardiovascular events, with early-onset and subacute events mainly being acute heart failure and atrial fibrillation, while certain pre-existing heart conditions increased the risk of these events.